GenBioPro, Inc.

Category: Drugs & Pharmaceuticals

GenBioPro, Inc. (GBP) is a private, specialty biotechnology company that is engaged in the regulatory approval and commercialization of biotechnology products. The Company has leveraged relationships with biotechnology product manufacturers in China and India to provide high quality recombinant proteins that can be sold at tremendously reduced costs, thus lowering the price of life-saving medicines in the U.S. and elsewhere. GBP's primary mission is to gain regulatory market approvals in the U.S., E.U., and other global markets for a significant pipeline of low cost, high quality, life-saving biotechnology products.

GenBioPro is focused on finishing the last steps of development, manufacturing, and regulatory approval of its product pipeline for sales in all major global markets. In addition, GBP will provide life-saving, high-tech products to developing countries to improve human life of people in the much-needed, under-served areas of the world.

GenBioPro's initial focus is to commercialize and sell recombinant human insulin. This product has been or will be registered and sold in the countries of Africa, Latin America, and Eastern Europe, while being developed for approvals in U.S., Canada, Mexico, and in the E.U. After insulin has been approved, revenues will be used to commercialize growth hormone and erythropoietin.